- AbCellera (Nasdaq:ABCL) stock price rose 0.42% in the last trading session. That’s why it happened.
AbCellera (Nasdaq:ABCL) stock price rose 0.42% in the last trading session. Investors react positively to AbCellera by announcing that bebtelovimab (LY-CoV1404), the second antibody developed through AbCellera’s collaboration with Eli Lilly and Company (Lilly), has received Emergency Use Authorization (EUA) ) from the United States Food and Drug Administration (FDA). Bebtelovimab is licensed for the treatment of mild to moderate COVID-19 in adults and pediatric patients (aged 12 years and older weighing at least 40 kg) with positive direct test results for SARS-CoV -2, and who are at high risk of progression to severe COVID-19, including hospitalization or death, and for whom alternative FDA-approved or cleared COVID-19 treatment options are not available or clinically appropriate. The authorized dosage of bebtelovimab is 175 mg by intravenous injection over at least 30 seconds.
As previously announced, Lilly had entered into a purchase agreement with the US government to supply up to 600,000 doses of bebtelovimab by March 31, 2022, with an option for an additional 500,000 doses by July 31, 2022.
And pseudovirus and authentic virus testing confirms that bebtelovimab neutralizes the omicron variant of the coronavirus – currently the predominant variant in the United States and pseudovirus testing with bebtelovimab demonstrates that it retains neutralization against all other known variants of the coronavirus. interest and concern, including BA.2. Previously reported data show that bebtelovimab is highly potent and binds to a rarely mutated region of the SARS-CoV-2 spike protein (Westendorf et al, biorxiv, updated Jan 7, 2022).
AbCellera’s response to COVID-19
AbCellera initially mobilized its pandemic response platform against COVID-19 in February 2020, resulting in the
discovery of bamlanivimab, the first monoclonal antibody treatment for COVID-19 to be tested in humans and cleared for emergency use by the US FDA. And Bbamlanivimab alone and with other antibodies has treated at least 700,000 patients, preventing COVID-19-related hospitalizations and deaths.
AbCellera’s second monoclonal antibody treatment for COVID-19, bebtelovimab, was developed to combat emerging variants. Pseudovirus and authentic virus testing confirmed that bebtelovimab maintains binding and neutralizing activity on currently known and reported variants of concern. And it’s being studied for the treatment of mild to moderate COVID-19 both as monotherapy and with other antibodies.
AbCellera’s efforts to respond to the COVID-19 pandemic have identified thousands of unique human anti-SARS-CoV-2 antibodies. These include bamlanivimab, bebtelovimab and other antibodies that are in various stages of testing by AbCellera and its partners.
Bamlanivimab and bebtelovimab were developed from antibodies that were discovered using AbCellera’s Pandemic Response Platform in partnership with the Vaccine Research Center (VRC) of the National Institutes for Allergy and Infectious Diseases (NIAID). And AbCellera’s partner, Lilly, is responsible for the development, manufacturing and distribution of bamlanivimab and bebtelovimab.
AbCellera’s pandemic response capabilities have been developed over the past four years under the Defense Advanced Research Projects Agency’s (DARPA) Pandemic Prevention Platform (P3) program. And the goal of the P3 program is to establish a robust technology platform for pandemic response capable of developing field-ready medical countermeasures within 60 days of isolation of an unknown viral pathogen. .
“At the start of the COVID-19 pandemic, we and our partners prioritized speed in delivering therapies to patients. This resulted in the discovery of bamlanivimab, the first COVID-19 antibody to reach the clinic and receive emergency use authorization from the FDA. We then redirected our efforts towards the discovery of a next-generation therapeutic antibody, this time emphasizing maximum potency and the extent of neutralization. This led to the discovery of bebtelovimab, which neutralizes all known variants of concern, and is the most potent antibody in development against the Omicron variant, including BA.2. The discovery of two approved therapeutic antibodies less than a year apart demonstrates the power of our platform and its potential to rapidly generate the best therapies for our partners.
— Carl Hansen, Ph.D., CEO of AbCellera
Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.